Related Experiment Video

Updated: Aug 25, 2026

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
09:54

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

BMD is reduced in HIV-infected men irrespective of treatment

C Amiel1, A Ostertag, L Slama

  • 1Department of Infectious Disease, Hôpital Tenon, Paris, France.

Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|March 26, 2004
PubMed

Insights

HIV-infected patients experience decreased bone density regardless of antiretroviral therapy. Low body mass and increased bone resorption markers are linked to lower bone density in these individuals.

Area of Science:

  • Bone Metabolism and HIV Research
  • Endocrinology and Osteoporosis

Background:

  • Osteoporosis is a recognized complication in HIV-infected (HIV+) patients.
  • Previous research suggested a potential link between osteoporosis and protease-inhibitor (PI) treatments in HIV+ individuals.

Purpose of the Study:

  • To assess bone density in HIV+ men receiving different antiretroviral therapies (with or without PIs) and untreated HIV+ men.
  • To investigate the relationship between bone density, HIV treatments, body composition, and bone remodeling markers.

Main Methods:

  • Compared bone mineral density (BMD) Z-scores of HIV+ men (treated and untreated) with age-matched HIV-negative controls.
  • Analyzed correlations between BMD, body mass index (BMI), lipodystrophy, and bone remodeling markers (bone alkaline phosphatase, urinary cross-laps/Cr, TNFalpha).

Main Results:

  • HIV+ patients exhibited significantly lower BMD at the lumbar spine and femoral neck compared to controls.
  • The prevalence of osteoporosis was higher in HIV+ patients (16%) versus HIV-negative individuals (4%).
  • Low BMI and elevated bone resorption markers were associated with decreased bone density in HIV+ patients, irrespective of treatment status.

Conclusions:

  • HIV infection, not antiretroviral therapy, is associated with decreased bone density.
  • Low bone density in HIV+ patients is linked to lower body weight and increased bone resorption.
  • Further research is needed to understand the mechanisms and management of osteoporosis in HIV+ individuals.
Abstract

More Related Videos

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Amebiasis01:28

Amebiasis

Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...